Pei Y - Search Results

1

Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B.

He H, Dang Y, Dai F, Guo Z, Wu J, She X, Pei Y, Chen Y, Ling W, Wu C, Zhao S, Liu JO, Yu L. He H, et al. Among authors: pei y. J Biol Chem. 2003 Aug 1;278(31):29278-87. doi: 10.1074/jbc.M303800200. Epub 2003 May 11. J Biol Chem. 2003. PMID: 12740394 Free article.

2

Molecular cloning and characterization of rat LC3A and LC3B--two novel markers of autophagosome.

Wu J, Dang Y, Su W, Liu C, Ma H, Shan Y, Pei Y, Wan B, Guo J, Yu L. Wu J, et al. Among authors: pei y. Biochem Biophys Res Commun. 2006 Jan 6;339(1):437-42. doi: 10.1016/j.bbrc.2005.10.211. Epub 2005 Nov 14. Biochem Biophys Res Commun. 2006. PMID: 16300744

3

Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation.

Pei Y, Zhu P, Dang Y, Wu J, Yang X, Wan B, Liu JO, Yi Q, Yu L. Pei Y, et al. J Immunol. 2008 Jan 1;180(1):222-9. doi: 10.4049/jimmunol.180.1.222. J Immunol. 2008. PMID: 18097023

4

IL-2 mRNA stabilization upon PMA stimulation is dependent on NF90-Ser647 phosphorylation by protein kinase CbetaI.

Zhu P, Jiang W, Cao L, Yu W, Pei Y, Yang X, Wan B, Liu JO, Yi Q, Yu L. Zhu P, et al. Among authors: pei y. J Immunol. 2010 Nov 1;185(9):5140-9. doi: 10.4049/jimmunol.1000849. Epub 2010 Sep 24. J Immunol. 2010. PMID: 20870937

5

Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.

Ding H, Pei Y, Li Y, Xu W, Mei L, Hou Z, Guang Y, Cao L, Li P, Cao H, Bian J, Chen K, Luo C, Zhou B, Zhang T, Li Z, Yang Y. Ding H, et al. Among authors: pei y. Bioorg Med Chem. 2021 Dec 15;52:116512. doi: 10.1016/j.bmc.2021.116512. Epub 2021 Nov 10. Bioorg Med Chem. 2021. PMID: 34801827

6

Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.

Yang X, Wang Z, Pei Y, Song N, Xu L, Feng B, Wang H, Luo X, Hu X, Qiu X, Feng H, Yang Y, Zhou Y, Li J, Zhou B. Yang X, et al. Among authors: pei y. Eur J Med Chem. 2021 Jun 5;218:113341. doi: 10.1016/j.ejmech.2021.113341. Epub 2021 Mar 11. Eur J Med Chem. 2021. PMID: 33780898

7

Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1).

Liu L, Zhu R, Li J, Pei Y, Wang S, Xu P, Wang M, Wen Y, Zhang H, Du D, Ding H, Jiang H, Chen K, Zhou B, Yu L, Luo C. Liu L, et al. Among authors: pei y. J Med Chem. 2022 Feb 10;65(3):2174-2190. doi: 10.1021/acs.jmedchem.1c01686. Epub 2022 Jan 28. J Med Chem. 2022. PMID: 35089030

8

Discovery of a Highly Potent, Selective and Efficacious USP7 Degrader for the Treatment of Acute Lymphoblastic Leukemia.

Xu M, Fu J, Pei Y, Li M, Kan W, Yan R, Xia C, Ma J, Wang P, Zhang Y, Gao Y, Yang Y, Zhou Y, Li J, Zhou B. Xu M, et al. Among authors: pei y. J Med Chem. 2024 Aug 8;67(15):13197-13216. doi: 10.1021/acs.jmedchem.4c01134. Epub 2024 Jul 19. J Med Chem. 2024. PMID: 39028938

9

Enhancement of dissolution of cyclosporine A using solid dispersions with polyoxyethylene (40) stearate.

Liu C, Zhu SJ, Zhou Y, Wei YP, Pei YY. Liu C, et al. Among authors: pei yy. Pharmazie. 2006 Aug;61(8):681-4. Pharmazie. 2006. PMID: 16964710

10

Amplification and up-regulation of microRNA-30b in oral squamous cell cancers.

Shao C, Yu Y, Yu L, Pei Y, Feng Q, Chu F, Fang Z, Zhou Y. Shao C, et al. Among authors: pei y. Arch Oral Biol. 2012 Aug;57(8):1012-7. doi: 10.1016/j.archoralbio.2012.04.002. Epub 2012 Apr 26. Arch Oral Biol. 2012. PMID: 22542163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,726 results

Search Page

Filters